Introduction
The activity of nuclear factor kappa B (NF-kB) proteins is regulated by hundreds of different stimuli in all cell types, with many functional consequences (Pahl, 1999; Perkins and Gilmore, 2006) . The general framework of the canonical and noncanonical pathways leading to activation of NF-kB via degradation of IkB and nuclear translocation of NF-kB has been reviewed elsewhere (Hayden and Ghosh, 2004; Gilmore, 2006) . While common themes exist for induction of NF-kB, for example, many inducers of NF-kB work through induction of the IkB kinase (IKK) complex, there are also numerous exceptions and alternative pathways of activation. Nevertheless, regardless of the stimulus, all pathways leading to NF-kB activation rely on inducing numerous post-translational modifications of either the IKKs, the IkBs or the NF-kB subunits themselves. Since induction of NF-kB involves its regulated nuclear localization, there are many critical cytoplasmic modifications required to either inactivate the IkB inhibitory proteins or to activate the NF-kB subunits directly. Of possibly equal importance, the function of NF-kB complexes is also controlled by many nuclear modifications, which can regulate transcriptional activity, DNA binding and target gene specificity. In addition, the tight temporal control of NF-kB activity means that pathways exist to limit its time in the nucleus and posttranslational modifications of the subunits can also contribute to the termination of the NF-kB response. This review discusses these modifications and how they contribute to each step of the NF-kB pathway.
Activation of the IKK complex
Induction of nuclear NF-kB activity by many stimuli, particularly those involved in the immune and inflammatory responses as well as some genotoxic agents and cellular stresses, requires the activation of the IKK complex (Hayden and Ghosh, 2004; Perkins and Gilmore, 2006) . Although many upstream signaling pathways lead to IKK activation, there are a number of common features associated with stimulation of IKK catalytic activity.
Ubiquitination of NEMO
The first step in IKK activation involves modification of the regulatory subunit of the IKK complex, NF-kB essential modifier (NEMO, also known as IKKg), through K63-linked polyubiquitination (Burns and Martinon, 2004; Chen, 2005; Krappmann and Scheidereit, 2005) (Figure 1 ; Table 1 ). In contrast to K48-linked ubiquitination, K63 linkages do not lead to proteasomal degradation, but in this case function as a binding site for other signaling molecules required for activation of the IKK catalytic subunit IKKb (Burns and Martinon, 2004; Chen, 2005; Krappmann and Scheidereit, 2005) . There are multiple NEMO ubiquitin E3 ligases, which vary depending upon the activating pathway (Burns and Martinon, 2004; Chen, 2005 ; Krappmann and Figure 1 Post-translational modifications and structure of the IKK subunits. Shown are schematic diagrams of the principal structural motifs of NEMO, IKKa and IKKb in relation to the known post-translational modifications that regulate their activity. It is possible that IKKa may undergo similar modifications to those seen in IKKb, but these have not yet been described in the literature. Phosphorylations at the C-terminus of IKKb are indicated as being approximately 10, since the exact number were not definitively established by the original mutagenesis studies (Delhase et al., 1999) . Numbering is from the human proteins, although some definitions of where a domain begins and ends might differ between publications. Abbreviations: CC1 and CC2, coiled coil regions 1 and 2; LZ, leucine zipper motif; ZF, zinc-finger domain; HLH, helix-loop-helix domain; NBD, NEMO-binding domain. The code for the different modifications is shown in the figure. Zhou et al., 2004) . TRAF6, as well as other family members such as TRAF2 and 5, also mediate NEMO polyubiquitination in response to tumor necrosis factor a (TNF) and interleukin-1 (IL-1) receptor signaling. By contrast, bacterial infection can result in nucleotide binding oligomerization domain 2 (NOD2, also known as CARD15) and receptor interacting protein 2 (RIP2)-dependent K63-linked polyubiquitination of NEMO at lysine 285 (Abbott et al., 2004) . TNF signaling has also been reported to result in the inhibitor of apoptosis protein 1 (c-IAP1)-dependent, K6-linked ubiquitination of NEMO within its zinc-finger region (Tang et al., 2003) .
IKK subunit modification NEMO ubiquitination is just one component in a complex series of ubiquitin-based modifications of the signaling molecules involved in IKK complex activation (Burns and Martinon, 2004; Chen, 2005; Krappmann and Scheidereit, 2005) . These include K63-linked autoubiquitination of TRAF2 and TRAF6, as well as K63-linked polyubiquitination of the RIP1 kinase. Interestingly, it has recently been shown that NEMO itself is a K63-linked polyubiquitin-binding protein and can bind ubiquitinated RIP1 (Ea et al., 2006; Wu et al., 2006a) . Therefore, this cascade of modifications may also serve to oligomerize and activate members of the IKK signaling pathway. Polyubiquitination of these signaling proteins also allows targeting of IKK activating kinases to the complex. The best characterized of these kinases is TGFb-activated kinase (TAK1), which has been reported to be involved in TNF-, IL-1-, Toll-like receptor (TLR)-and TCR-mediated activation of NF-kB (Chen, 2005; Krappmann and Scheidereit, 2005; Chen et al., 2006) . TAK1 is associated with the TAK binding proteins, TAB2 and TAB3, which are themselves K63-linked polyubiquitin-binding proteins, and therefore TAB2 and TAB3 can be recruited to the IKK complex by TRAF2/6, RIP1 and potentially NEMO itself (Chen, 2005; Krappmann and Scheidereit, 2005; Chen et al., 2006) . This allows TAK1-mediated phosphorylation of IKKb within its activation loop at Ser-177 and Ser-181, resulting in an active IKK complex, which is now competent for IkB phosphorylation and NF-kB pathway induction (Wang et al., 2001) (Figure 1 ; Table 1 ).
Other putative IKKb-activating kinases have been described, such as PDK1, SGK and MEKK3 (Yang et al., 2001; Huang et al., 2004; Lee et al., 2005; Tanaka et al., 2005; Zhang et al., 2005) . However, the mechanisms by which these other kinases might be targeted to the IKK complex are not well characterized. In addition, IKKb autophosphorylation, catalysed by oligomerization of the IKK complex, might play a role in IKK activation under some circumstances. IKKb activation loop phosphorylation at Ser-177 and Ser-181 has also been reported to lead to mono-ubiquitination of IKKb at Lys-163 (Carter et al., 2005) . Mutation of Lys-163 impairs subsequent IKKb auto-phosphorylation of further C-terminal serine residues in cells (Delhase et al., 1999; Schomer Miller et al., 2006) , but not in vitro (Carter et al., 2005 ). An alternative pathway leading to IKKb activation loop phosphorylation has also been described: this pathway involves the c-Src-dependent phosphorylation of Tyr-188 and Tyr-199 of IKKb in response to TNF and 12-O-tetradecanoylphorbol-13-acetate (TPA) stimulation (Huang et al., 2003b) . Given the diversity of NF-kB signaling pathways, it is possible that other phosphorylation events also lead to IKKb activation.
IKKb has also been reported to be a target of constitutive S-nitrosylation at Cys-179, a site within the activation loop (Reynaert et al., 2004) . This modification inhibits IKKb activity, and TNF stimulation results in denitrosylation at Cys-179 (Reynaert et al., 2004) . Whether this denitrosylation of Cys-179 is directly linked to active site phosphorylation is not known. Interestingly, this same cysteine residue is also required for some natural product-mediated inhibition of IKKb (Liang et al., 2006b) .
A further regulatory event post-IKKb activation has also been reported. This involves the IKKb-mediated phosphorylation of NEMO at Ser-31, Ser-43 and Ser-376, and has been observed following TNF stimulation and expression of the Tax viral oncoprotein (Prajapati and Gaynor, 2002; Carter et al., 2003) . Further NEMO phosphorylations at residues in the center of the protein have also been reported but were only observed upon deletion of the C terminus of NEMO (Prajapati and Gaynor, 2002) . The possible effect of these phosphorylations on NEMO activity is unclear. They could potentiate IKK activation or alternatively might serve to downregulate IKK activity, possibly by targeting NEMO to deubiquitinating enzymes such as the tumor suppressor CYLD or A20 (Chen, 2005; Krappmann and Scheidereit, 2005) to NEMO, TRAF6 and RIP. Such deubiquitinating enzymes have been shown to have an important inhibitory effect on NF-kB signaling and to be involved in the termination of the NF-kB response (Chen, 2005; Krappmann and Scheidereit, 2005) .
Activation of IKK in response to genotoxic stress An alternative, NEMO-and IKKb-dependent pathway, which bears some similarities but also key differences to the classical signaling pathway described above, is activated in response to cellular exposure to DNAdamaging agents. While activation of the classical NF-kB pathway is typically rapid, occurring within minutes of cellular exposure to a stimulus, genotoxic agents induce NF-kB with delayed kinetics (Huang et al., 2003a; Wu et al., 2006b) . At least in part, this appears to result from an alternative pathway of NEMO modification and regulation. Here, in response to stress-activated pathways induced as a consequence of exposure to DNA-damaging agents (but not necessarily DNA damage per se), NEMO translocates to the nucleus where it becomes sumoylated on Lys-277 and Lys-309 (Huang et al., 2003a; Wu et al., 2006b) (Figure 1 ; Table 1 ). This results in phosphorylation of NEMO on Ser-85 by the ATM (Ataxia Telangiectasia Mutated) checkpoint kinase (Wu et al., 2006b ). This in turn results in the replacement of NEMO Sumo modification by mono-ubiquitination (Huang et al., 2003a) . This mono-ubiquitination leads to the nuclear export of NEMO as a complex with ATM, which is subsequently required for the further activation of the IKK complex in a manner that requires the IKK-associated protein ELKS (a protein rich in glutamate (E), leucine (L), lysine (K) and serine (S)) (Wu et al., 2006b) . Whether this pathway is activated in response to all genotoxic stresses in all cell types is currently unclear.
Activation of the non-canonical NF-kB pathway In addition to pathways that culminate in NEMOdependent activation of IKKb and the phosphorylation and degradation of IkB proteins, there exists a parallel signaling cascade, the 'non-canonical' NF-kB pathway, that results in IKKa activation and the processing of the p100 NF-kB subunit to p52 (Bonizzi and Karin, 2004) . Only certain cellular stimuli, such as stimulation of the CD40 and lymphotoxin-b receptors, BAFF, LPS, and the latent membrane protein-1 of Epstein-Barr virus, induce NF-kB activity through the non-canonical pathway (Bonizzi and Karin, 2004) . These stimuli appear to converge upon NF-kB-inducing kinase (NIK) , which in turn is required for phosphorylation of IKKa at Ser-176 and Ser-180 within its activation loop (Ling et al., 1998; Senftleben et al., 2001) (Figure 1 ; Table 1 ). In this pathway, IKKa is thought to exist as a homodimer, independent of NEMO and IKKb (Bonizzi and Karin, 2004 ). It will be interesting to see whether, like the classical pathway, there is a role for K63-linked polyubiquitination of NIK, IKKa or other proteins in the non-canonical pathway. Activation of the phosphatidylinositol-3-OH kinase (PI(3)K) pathway has, in some cell types, been shown to lead to Akt/Protein Kinase B phosphorylation of IKKa at Thr-23 and subsequent activation of the non-canonical pathway (Gustin et al., 2004 (Gustin et al., , 2006 Ozes et al., 1999) .
Modification and degradation of IjB proteins
The principal physiological function of activated IKKb is to phosphorylate one of the three major cytoplasmic inhibitors of NF-kB: IkBa, b or e (Mercurio et al., 1997; Whiteside et al., 1997; Woronicz et al., 1997; Zandi et al., 1997; Wu and Ghosh, 2003; Hayden and Ghosh, 2004) . All of these IkB proteins contain a conserved motif near their N termini consisting of two serine residues that are sites of phosphorylation by IKKb and one or two inducibly ubiquitinated lysine residues (Amir et al., 2004; Hayden and Ghosh, 2004) (Figure 2 ; Table 2 ). In contrast to NEMO, IkB ubiquitination is K48-linked, which results in proteolytic degradation by the proteasome (Chen, 2005; Krappmann and Scheidereit, 2005) . Ser-32/36 phosphorylation of IkBa results in binding of the SCF-bTrCP E3 ligase and a member of the UBC4/5 E2 ligase family, leading to ubiquitination of IkBa at lysines 21 and 22 (Chen, 2005; Krappmann and Scheidereit, 2005) . Degradation of ubiquitinated IkBa occurs rapidly in cells, whereas degradation of IkBb and e is delayed, or sometimes does not occur at all (Thompson et al., 1995; Weil et al., 1997; Whiteside et al., 1997; Fischer et al., 1999; Wu and Ghosh, 2003) . At least in part, this difference in the kinetics of degradation of the various IkBs is the result of the more efficient phosphorylation of the IkBa serine residues by IKKb (Wu and Ghosh, 2003) .
IkBa can also be inactivated by kinases other than IKKb in the classical activation pathway. For example, a CK2 (casein kinase II)-dependent pathway has been described that is activated in response to short wavelength ultraviolet (UV-C) light treatment or expression of the Her2/Neu oncogene (Romieu-Mourez et al., 2002; Kato et al., 2003) . Here, phosphorylation of IkBa is not targeted to Ser-32 and Ser-36, which means a bTrCP-independent mechanism of IkBa protein inactivation or degradation is required. Indeed, with Her2/ Neu activation, IkBa degradation is a consequence of the action of calpain, rather than the proteasome (Romieu-Mourez et al., 2002) . CK2 phosphorylation of IkBa has been mapped in vitro to Ser-283, Ser-289 and Ser-293 and Thr-291 and Thr-299, all of which lie within the IkBa PEST domain, a motif associated with protein degradation (Lin et al., 1996; McElhinny et al., 1996; Schwarz et al., 1996; Kato et al., 2003) (Figure 2 ; Table 2 ). It is likely that CK2-mediated activation of NF-kB is cell type or context specific. Furthermore, whether other kinases can similarly phosphorylate the PEST domain and whether this is a common mechanism of IkBa regulation is currently unknown. CK2 also phosphorylates the IkBb PEST domain at Ser-313 and Ser-315, resulting in the loss of IkBb mediated inhibition of NF-kB complexes (Chu et al., 1996; McKinsey et al., 1997) .
IkBa can also be inactivated by tyrosine kinases in response to a wide range of stimuli, such as hypoxia/ reoxygenation, hydrogen peroxide stimulation, treatment with nerve growth factor and the tyrosine phosphatase inhibitor pervanadate (Koong et al., 1994; Imbert et al., 1996; Singh et al., 1996; Mukhopadhyay et al., 2000; Schoonbroodt et al., 2000; Bui et al., 2001) . In bone marrow macrophages, TNF-induced activation of NF-kB has also been reported to occur through this IkBa tyrosine phosphorylation pathway (Abu-Amer et al., 1998) . In these situations, stimuli lead to phosphorylation of IkBa at Tyr-42 and putative Tyr-42 kinases include p56-lck, Syk and c-Src (Abu-Amer et al., 1998; Fan et al., 2003; Mahabeleshwar and Kundu, 2003; Takada et al., 2003) . In some instances, Tyr-42 phosphorylation results in IkBa being degraded, whereas in other cases, the result is dissociation of IkBa from the NF-kB complex (without degradation).
IkBa can also be rendered refractory to degradation by the classical pathway by SUMO-1 (small ubiquitin-like modifier 1) modification at Lys-21, which has the effect of inhibiting ubiquitination at the same residue (Desterro et al., 1998) . Sumoylation is inhibited by Ser-32/Ser-36 phosphorylation of IkBa and so can be thought of as an antagonistic pathway to NF-kB activation. However, pools of sumoylated proteins are generally found at low steady-state levels within the cell, suggesting this simple prevention of IkBa ubiquitination is unlikely to be an efficient means of antagonizing NF-kB induction. Moreover, protein sumoylation frequently requires nuclear localization (Rodriguez et al., 2001) . It is possible, therefore, that sumoylation may be involved in the shuttling of IkBa to the nucleus, where it binds to NF-kB complexes, inactivating them and relocating them back to the cytoplasm.
Cytoplasmic activation and processing of NF-jB subunits
In addition to IkB inactivation, other important modification and processing events, involving the NF-kB subunits themselves, occur in the cytoplasm of the cell. Most notably, there is the phosphorylation, ubiquitination and degradation of p100 and p105, the precursor proteins for the p52 and p50 NF-kB subunits. Both p100 and p105 contain IkB-like ankyrin repeats in their C-terminal halves, and prior to processing sequester their NF-kB subunit dimerization partners in the cytoplasm (Hayden and Ghosh, 2004) . Despite their obvious structural similarities, p100 and p105 are regulated by different pathways with very different functional consequences. Figure 2 Post-translational modifications and structure of the IkB subunits. Shown are schematic diagrams of the principal structural motifs of IkBa, IkBb, IkBe and Bcl-3 in relation to the known post-translational modifications that regulate their activity. Amino acid numbering is according to the human proteins, although some definitions of where a domain begins and ends might differ between publications. Abbreviations: ANK, Ankyrin repeats; PEST, domain rich in proline (P), glutamate (E), serine (S) and threonine (T). The code for the different modifications is shown in the figure.
Processing of p100
The non-canonical NF-kB pathway involves the activation of NIK and IKKa with the subsequent phosphorylation of p100 within its C-terminal domain at Ser-866 and Ser-870 (Senftleben et al., 2001; Xiao et al., 2001; Bonizzi and Karin, 2004) (Figure 3 ; Table 3 ). These phosphorylations create an SCF-bTrCP binding site in p100, homologous to those found in IkBs (Amir et al., 2004; Liang et al., 2006a) , and this triggers K48-linked ubiquitination of p100, for which Lys-856 is the anchoring residue (Amir et al., 2004) . Recently, it has been shown that phosphorylation of Ser-872 by IKKa might also represent a critical step required for p100 processing and may precede phosphorylation at Ser-866 and Ser-870 (Xiao et al., 2004) . Moreover, after being recruited to p100 in a Ser-866-and Ser-870-dependent manner, IKKa has been shown to also phosphorylate p100 at Ser-99, Ser-108, Ser-115 and Ser-123 (Xiao et al., 2004) . These sites of phosphorylation are also required for efficient processing of p100 to p52, but since they are located within the p52 Rel Homology Domain (RHD), they may also play a role regulating p52 DNA binding or dimerization.
Processing of p105
By contrast to p52/p100, the majority of p50 appears to be generated co-translationally in a constitutive manner (Lin et al., 1998) . Inducible processing of p105 can occur, although this frequently results in the complete degradation of p105 without p50 generation (Cohen et al., 2004; Hayden and Ghosh, 2004) . Unlike p100, IKKb is the p105 kinase and has been shown to phosphorylate Ser-927 and Ser-932, which form the SCF-bTrCP binding site (Orian et al., 2000; Lang et al., 2003) (Figure 3 ; Table 3 ). Phosphorylation of p105 at these serines induces ubiquitination at multiple lysine residues and results in the complete degradation of p105 (Cohen et al., 2004) . IKKb can also induce SCF-bTrCPindependent processing of p105, which, while distinct from co-translational processing, can also lead to p50 Figure 3 Post-translational modifications and structure of the NF-kB subunits. Shown are schematic diagrams of the principal structural motifs of Rel(p65), RelB, c-Rel, p105 (p50) and p100 (p52) in relation to the known post-translational modifications that regulate their activity. All NF-kB subunits may undergo similar modifications to highly conserved amino acids in the RHD. For example, these might include the equivalents of p105 Cys-62 and RelA Ser-276 and Ser-281. Analogous residues are present in all NF-kB subunits except for p52, which lacks the Ser-276 equivalent. p105 Ser-337 and c-Rel 267 are the equivalents of RelA Ser-276 while RelB Ser-368 is the equivalent of RelA Ser-281. RelA Cys-38 and c-Rel Cys 26 are the equivalents of p105 Cys-62. Not shown is RelA nitration at Tyr-66 and Tyr-152. Amino acid numbering corresponds to the human proteins, although some definitions of where a domain begins and ends might differ between publications. In particular, p100 numbering for C-terminal phosphorylations differs between reports as a result of sequencing errors in the original p52/p100 cDNA cloning papers. The numbering adopted here is that used in Liang et al. formation (Cohen et al., 2004) . Although dependent upon the ubiquitin system, this SCF-bTrCP-independent processing of p105 does not involve the ubiquitination of p105 seen with complete degradation (Cohen et al., 2004) . In resting cells, p105 is also phosphorylated at Ser-903 and Ser-907 by GSK3b. This stabilizes p105 but is required for subsequent inducible p105 processing in response to TNF stimulation (Demarchi et al., 2003) . Even though the inducible processing of p105 does not typically lead to the generation of p50, it does have an important regulatory role. The Tpl2 (Cot) kinase, which regulates MAP kinase pathway signaling, is found bound to a small portion of the cellular pool of p105 Waterfield et al., 2004) . In this state, Tpl2 is catalytically active and phosphorylates p105 at an unknown residue, but Tpl2 is unable to activate the MAP kinase pathway until released after p105 degradation (Babu et al., 2006) . This pathway provides an interesting mechanism through which the IKK pathway can crosstalk to the MAP kinase signaling pathway. However, only a small proportion of cellular p105 is bound to Tpl2, suggesting other consequences of p105 degradation, such as the release of dimerized NF-kB subunits.
Cytoplasmic modification of RelA
In addition to phosphorylation/ubiquitination-induced p100 and p105 processing, the RelA NF-kB subunit also undergoes cytoplasmic modification prior to nuclear translocation. These modifications can also stimulate NF-kB translocation to the nucleus, either in their own right or as separate activation pathways. In addition, phosphorylation of RelA in the cytoplasm may act to program its transcriptional functions in the nucleus.
In response to LPS, and probably other inducers, RelA is phosphorylated at the highly conserved Ser-276 residue by the catalytic subunit of protein kinase A (PKAc), which is in a complex with IkBa, suggesting coordinate IkB phosphorylation/degradation and RelA modification (Zhong et al., 1998 (Zhong et al., , 2002 (Figure 3 ; Table 4 ). p50 and c-Rel are also modified by PKAc at Ser-337 and Ser-267, respectively, the equivalent sites to RelA Ser-276 (Mosialos et al., 1991; Hou et al., 2003; Yu et al., 2004; Guan et al., 2005) (Figure 3 ; Table 3 ). Since this serine is also conserved in RelB (but not p52), it is probable that similar modification occurs with this subunit. Ser-276 in RelA is also phosphorylated by the MSK1 kinase, although this is a nuclear event (see below) (Vermeulen et al., 2003) . Phosphorylation at Ser-276 (and the analogous site in c-Rel) is thought to disrupt an intramolecular interaction between the RelA N and C termini, allowing DNA binding and p300/CBP coactivator interaction (Mosialos et al., 1991; Zhong et al., 1998; Zhong et al., 2002; Yu et al., 2004) . However, the analysis of relaÀ/À MEFs reconstituted with S276A mutant versions of RelA indicates that the effect of phosphorylation of this site can be very promoter specific (Anrather et al., 2005) , suggesting other effects might compensate for lack of phosphorylation at this site (see below) or that Ser-276 phosphorylation has a subtler effect on RelA function in cells. For example, Ser-276 phosphorylation may also affect subunit dimerization preference (Gapuzan et al., 2003) .
RelA is also inducibly phosphorylated in response to TNF stimulation at Thr-254, by an unknown kinase (Ryo et al., 2003) . This creates a phosphorylated pThrPro motif that allows binding by the peptidyl-prolyl isomerase Pin-1. The action of Pin-1 disrupts RelA's interaction with IkBa and induces NF-kB localization to the nucleus (Ryo et al., 2003) . This Pin-1-dependent mechanism also protects RelA from SOCS-1-mediated ubiquitination between residues 220-335 and subsequent proteolysis (Ryo et al., 2003) . As Thr-254 is within the RHD, its phosphorylation and subsequent proline isomerization at Pro-255 could be expected to also affect RelA DNA-binding or transcriptional activity.
Phosphorylation of RelA at Ser-536, a site within the transactivation domain, has also been described. This site is the target of many kinases, with multiple functional effects (see also below). Interestingly, one of the Ser-536 kinases is IKKb (Sakurai et al., 1999; Haller Mattioli et al., 2004; Buss et al., 2004b) . Whether phosphorylation at Ser-536 by IKKb is part of the activation mechanism leading to RelA nuclear translocation or a mechanism of cytoplasmically priming RelA's transactivation potential is unknown. However, phosphorylation of Ser-536 can also result in an IkB-independent mechanism of NF-kB activation (Bohuslav et al., 2004; Sasaki et al., 2005) . Specifically, in some cell types, induction of the p53 tumor suppressor results in RSK1 kinase activation (Bohuslav et al., 2004) , which in turn can phosphorylate RelA at Ser-536. Since activation of RSK1 is associated with its cytoplasmic to nuclear translocation, it is proposed that, in this instance, Ser-536 phosphorylation occurs in the nucleus. This results in RelA nuclear accumulation through disruption of the cytoplasmic/nuclear shuttling of NF-kB/IkB complexes that occurs in unstimulated cells (Bohuslav et al., 2004) . Under other circumstances, an opposite effect of Ser-536 phosphorylation on RelA activity has been proposed. Following activation by TNF, RelA can dynamically oscillate between the nucleus and cytoplasm (Nelson et al., 2004) . Moreover, nuclear RelA is rapidly dephosphorylated at Ser-536, suggesting that return to the cytoplasm is necessary, at least under some conditions, to reactivate NF-kB during over a sustained time course of activation (Nelson et al., 2004) . Other RelA phosphorylations may also require cytoplasmic reprogramming. For example, Ser-468 phosphorylation of RelA by IKKb has also been reported to be a cytoplasmic event (Schwabe and Sakurai, 2005 ) (see below).
Regulation of nuclear NF-jB transcriptional activity
Although many studies focus on the mechanisms and pathways that lead to NF-kB nuclear localization, it is now clear that the functions of nuclear NF-kB subunits are also highly regulated. Multiple nuclear modifications 
can affect DNA binding, interactions with coactivators and corepressors as well as the termination of the NF-kB response (Vermeulen et al., 2003; Chen and Greene, 2004; Viatour et al., 2005; Perkins and Gilmore, 2006) . To date, most studies have focused on RelA nuclear modification, and the analysis of nuclear modifications of other NF-kB subunits is extremely limited. However, even with RelA, we are only starting to appreciate the complexity of its nuclear regulation. It should also be noted that different studies offer different levels of proof that a specific kinase is modifying a particular site. In part, this results both from this being a relatively new area of study in the NF-kB field and also because in vitro kinase assays can be notoriously misleading while many small-molecule inhibitors of kinases lack specificity. Furthermore, many modifications are likely to differ between cell types and the nature of the NF-kB-inducing stimulus. Indeed, as can be seen with RelA phosphorylation at Ser-536 (see above and below), the effect of a phosphorylation can differ depending upon its context.
Phosphorylation of RelA
Multiple RelA phosphorylation sites and candidate kinases have now been described (Vermeulen et al., 2003; Viatour et al., 2005) . Broadly speaking, many of these phosphorylations have a modulatory role on NF-kB transcriptional activity. For example, phosphorylation of Ser-529 and Ser-536, which both lie within the TA1 subdomain of the RelA transactivation domain, can stimulate RelA transactivation (Vermeulen et al., 2003; Viatour et al., 2005) (Figure 3 ; Table 4 ). Phosphorylation at these sites has been detected in response to many inflammatory stimuli (Vermeulen et al., 2003; Viatour et al., 2005) . Multiple Ser-536 kinases have been described in addition to IKKb and RSK1, mentioned above. These include IKKa (see also below), IKKe (also known as IKKi) and NF-kB activating kinase (NAK, also known as TBK1, TANK-binding kinase 1) (Sakurai et al., 1999; Sizemore et al., 2002; Jiang et al., 2003; Buss et al., 2004b; Lawrence et al., 2005) . By contrast, to date, only CK2 has been described as a Ser-529 kinase (Wang et al., 2000) , although this probably represents the lower level of investigation that this site has received. It is noteworthy that IKKb and CK2 have also been described as inducers of NF-kB DNA binding, implying coordinate regulation of IkB degradation and nuclear transactivation potential. The TA1 domain of RelA contains many phosphorylatable residues, suggesting that other regulatory events might occur in this region. Recently, phosphorylation within the TA2 subdomain of RelA has also been described. Ser-468 is inducibly phosphorylated in response to TNF, IL-1b and T-cell stimulation and has been described as a target for GSK3b, IKKe and IKKb (Buss et al., 2004a; Schwabe and Sakurai, 2005; Mattioli et al., 2006) . Ser-468 phosphorylation has been described as both stimulating and inhibiting RelA transactivation. Interestingly, while IKKe-mediated phosphorylation at Ser-468 was described as a nuclear event (Mattioli et al., 2006) , IKKb phosphorylation at this site was reported to be cytoplasmic (Schwabe and Sakurai, 2005) . Phosphorylation of Thr-505, within the RelA TA2 domain, inhibits RelA transactivation by inducing increased association with HDAC1 and can result in transcriptional repression of some NF-kB target genes, such as Bcl-xL (Rocha et al., 2005; Campbell et al., 2006) . Phosphorylation of RelA at Thr-505 requires the Chk1 checkpoint kinase and is induced by the ARF tumor suppressor or treatment of U-2 OS cells with the chemotherapeutic drug cisplatin (Rocha et al., 2005; Campbell et al., 2006) . Other inducers of Chk1 activity do not appear to induce Thr-505 phosphorylation, suggesting that mechanisms exist to target Chk1 to RelA under only certain circumstances. Phosphorylation at Thr-435 has also been implicated as a negative regulator of RelA transactivation (Yeh et al., 2004) . Here, the Thr-435 kinase is unknown, but dephosphorylation of this site by protein phosphatase 4 (PP4) has been suggested to occur in response to cisplatin treatment (Yeh et al., 2004) . Interestingly, all of these RelA phosphorylations occur within evolutionarily conserved subdomains of the TA2 domain, suggesting that they regulate the association of RelA with coactivators and corepressors. Indeed, the TA2 domain of RelA has been demonstrated to interact with the CBP coactivator protein (Zhong et al., 2002) .
Ser-311, which also lies within the RelA transactivation domain, but close to the junction with the RHD, is inducibly phosphorylated by the atypical protein kinase C, PKCz, in response to TNF stimulation (Duran et al., 2003) . Within the RHD, as discussed above, TNF stimulation leads to Ser-276 phosphorylation in the nucleus by MSK1 (Vermeulen et al., 2003) . Furthermore, Ser-281 is inducibly phosphorylated in response to LPS by an unknown kinase (Anrather et al., 2005) . Ser-276 and Ser-281 form a highly conserved motif that is also present in all other NF-kB subunits except p52/ p100, which lacks its equivalent of Ser-276 (although it retains the Ser-281 site) (Anrather et al., 2005) . The same study also showed Ser-205 of RelA can be phosphorylated in response to LPS. Moreover, mutation of these sites did not totally inactivate RelA. Rather they had a modulatory role, affecting RelA's ability to transactivate some promoters while leaving others essentially unaffected (Anrather et al., 2005) . This is likely to be a theme of many of these modifications of NF-kB subunits. That is, the effects of these modifications will modulate target gene specificity and timing, as opposed to being simple on-off switches for activity and inactivity. Indeed, differential modification of RelA is likely to underpin the differences in RelA functionality observed in response to diverse regulators such as genotoxic agents, tumor suppressors and oncogenes, which are known to affect RelA phosphorylation but at unknown sights (Perkins and Gilmore, 2006) .
Acetylation of RelA
RelA is also inducibly acetylated at a number of sites and these have different effects on its activity Quivy and Van Lint, 2004) (Figure 3 ; Table 4 ). The transcriptional coactivators p300 and CBP can acetylate RelA at Lys-218, -221 and -310. Lys-221 acetylation enhances RelA DNA binding, and in conjunction with Lys-218 acetylation, inhibits the association of RelA with newly synthesized IkBa, which otherwise could act to relocate NF-kB complexes to the cytoplasm (Chen et al., 2002) . By contrast, Lys-310 acetylation stimulates RelA transactivation (Chen et al., 2002) . RelA is also acetylated at Lys-122 and Lys-123, which has an inhibitory effect (see below) (Kiernan et al., 2003) . It is interesting to note that Lys-310 lies adjacent to the PKCz phosphorylation site at Ser-311, implying a possible functional relationship. Indeed, a link between phosphorylation and acetylation has been demonstrated, with Ser-276 and Ser-536 phosphorylation resulting in increased p300 binding and therefore enhanced RelA acetylation at Lys-310 Chen et al., 2005) . Furthermore, Lys-310 deacetylation by corepressor complexes also provides a mechanism to inhibit RelA activity Yeung et al., 2004) .
Other NF-kB subunits Apart from those modifications leading to processing of p100 and p105 (see above), the post-translational modification of NF-kB subunits other than RelA has received relatively little attention. c-Rel-mediated transactivation is stimulated by phosphorylation within its transactivation domain at Ser-471 by PKCz in response to TNF and possibly also by NIK (Martin and Fresno, 2000; Martin et al., 2001; Sa´nchez-Valdepen˜as et al., 2006) (Figure 3 ; Table 4 ). Other residues in the c-Rel transactivation domain are also phosphorylated (Martin and Fresno, 2000) , and mutation of Ser-454 and Ser-460 has been shown to affect c-Rel function (Starczynowski et al., 2005) . In addition, IKKe has also been shown to phosphorylate the c-Rel transactivation domain at unknown sites and stimulate its nuclear accumulation (Harris et al., 2006) . Mouse c-Rel is phosphorylated in vitro at an ERK kinase consensus site in its transactivation domain (Ser-451) (Fognani et al., 2000) but, although otherwise conserved, this exact site is not present in the human or chimpanzee forms of the protein (Starczynowski et al., 2005) . c-Rel, in common with RelA and p105, is also inducibly tyrosine phosphorylated at unknown sites (Neumann et al., 1992; Druker et al., 1994; Liu and Beller, 2002; Kang et al., 2003; Pellegatta et al., 2003) .
RelB is phosphorylated at Ser-368, the equivalent of Ser-281 in RelA, and this regulates its dimerization with p100 (Maier et al., 2003) . Similarly, as discussed above, p50 is phosphorylated at the RelA Ser-276 equivalent, that is, Ser-337 (Hou et al., 2003; Guan et al., 2005) . Thus, it is likely that the equivalents of RelA Ser-276 and Ser-281, as well as other conserved sites, can be modified in all NF-kB subunits. p50 DNA-binding activity can also be stimulated by acetylation at Lys-431, Lys-440 and Lys-441 (Furia et al., 2002; Deng et al., 2003) . Acetylation of p52/p100 has also been reported with divergent effects. One study suggests that acetylation induces increased processing of p100 to p52 (Hu and Colburn, 2005) , while another study indicates that p300-dependent acetylation of p52 enhances its DNAbinding activity . These differences could reflect acetylation at different sites, but the sites of acetylation on p52/p100 have not yet been mapped.
Bcl-3 has structural similarity to the IkBs, but Bcl-3 is primarily nuclear and functions as a transcriptional coactivator for p50 and p52 (Hayden and Ghosh, 2004) . Bcl-3 is highly phosphorylated, but little is known about the sites of these modifications or their effects on Bcl-3 activity. One study has shown that Bcl-3 is constitutively phosphorylated by GSK-3b at Ser-394 and Ser-398 and that this phosphorylation promotes the degradation of Bcl-3 (Viatour et al., 2004) . Inhibition of GSK-3b upon cellular stimulation will therefore lead to Bcl-3 stabilization and stimulation of Bcl-3-dependent target gene expression. This is another example of a pathway through which GSK-3b acts to suppress NF-kB activity in unstimulated cells (see p105 and RelA phosphorylation above). Interestingly, Bcl-3 nuclear localization in keratinocytes has recently been shown to be regulated by K-63-linked ubiquitination at unknown sites (Massoumi et al., 2006) . Moreover, loss of the CYLD tumor suppressor and deubiquitinase results aberrantly nuclear Bcl-3 and p50/p52 dependent stimulation of Cyclin D1 expression (Massoumi et al., 2006) .
Termination of the NF-jB response
Under normal circumstances the duration of the NF-kB response is inherently self-limiting and a number of negative feedback mechanisms have been described (Hayden and Ghosh, 2004; Perkins and Gilmore, 2006) . Post-translational modifications of the NF-kB subunits can also participate in termination of the NF-kB response.
Phosphorylation of RelA at Ser-536 by IKKa has been shown to stimulate its increased turnover in macrophages, in a process contributing to the resolution of inflammation (Lawrence et al., 2005) . This study provides yet another function for the RelA Ser-536 residue, suggesting that other factors, such as phosphorylation at other sites or the cellular context, are critical determinants of the consequence of inducing this modification. Interestingly, ubiquitin-dependent proteolysis of promoter-bound RelA is also required for the efficient termination of NF-kB-dependent transcription (Saccani et al., 2004) , although whether this ubiquitination is triggered by prior phosphorylation is not known. It is also not known whether this ubiquitination of RelA is at the same site as that mediated by SOCS-1 and regulated by Pin-1, as described above (Ryo et al., 2003) . It is possible that inhibitory phosphorylations within the RelA transactivation domain, such as at Thr-505, also have a role in shutting down the NF-kB response. IKKa also regulates c-Rel turnover (Lawrence et al., 2005) , and c-Rel is also subject to ubiquitination between residues 427 and 480 that promotes c-Rel proteolysis (Chen et al., 1998) . The sites of any modifications of c-Rel that mediate these events and whether they are linked, are not known. RelB is also subject to phosphorylation-induced proteolytic turnover (Marienfeld et al., 2001) . This involves phosphorylation at Thr-84/ Ser-552 and is context-dependent, being seen with TCR or TPA/ionomycin stimulation but not with TNF stimulation (Marienfeld et al., 2001) .
The termination of NF-kB-dependent transcription can also potentially be mediated by acetylation of RelA at Lys-122 and Lys-123, which decreases its DNA-binding affinity (Kiernan et al., 2003) . In common with acetylation at lysines 218, 221 and 310 (see above), acetylation of Lys-122 and Lys-123 can be performed by p300 and CBP, implying a role both in activation and repression of the NF-kB response by these transcriptional coactivators.
Other modifications can inhibit NF-kB. Nitric oxide (NO)-mediated S-nitrosylation can inhibit p50 DNAbinding activity through modification of Cys-62 (Matthews et al., 1996) (Figure 3 ; Table 3 ). Indeed, modification of reactive cysteine residues provides a mechanism through which several oxidizing agents, natural products and natural product derivatives can inhibit both IKK and NF-kB subunits (Straus et al., 2000; Kwok et al., 2001; Garcia-Pineres et al., 2004; Park et al., 2005a; Liang et al., 2006c; Na and Surh, 2006) . Interestingly, epoxyquinone A inhibits RelA DNAbinding activity through Cys-38 modification, the equivalent of p50 Cys-62 (Liang et al., 2006b) . Furthermore, Cys-27 oxidation and alkylation of c-Rel prevent its phosphorylation and inhibit DNA-binding (Glineur et al., 2000) . Since this redox-sensitive cysteine residue, located in a DNA-binding loop, is conserved in all NF-kB subunits, this might prove a common mechanism of regulating NF-kB subunit function by oxidation, alkylation and other thiol-dependent modifications (Na and Surh, 2006) . NO can also induce RelA nitration at Tyr-66 and Tyr-152, the effect of which is dissociation from p50, increased association with IkBa and sequestration in the cytoplasm (Park et al., 2005b) .
Conclusions
The complexity and diversity of IKK, IkB and NF-kB protein modifications is striking. It is this complexity that enables the fine control of NF-kB function, which is required to regulate its diverse activities. Moreover, the catastrophic consequences of aberrant NF-kB activation require multiple regulatory pathways to ensure only appropriate activation and correct termination of the NF-kB response. Yet, it is also striking how much remains to be discovered and it is likely that we have only scratched the surface of the regulatory modifications of the NF-kB subunits. These modifications determine the specificity of NF-kBregulated gene expression and the functionality of nuclear NF-kB as a regulator of critical cellular pathways such as cell growth, cytokine secretion and apoptosis. There is also much still to discover about the IKK subunits and how they respond to such diverse stimuli. In particular, the growing list of functions for IKKa implies complex regulation of its activity. Understanding the effects of pathways leading to posttranslational modifications within the NF-kB signaling pathway will not only provide insights into the basic mechanisms of NF-kB regulation but, given the role of these proteins in human health and disease, could also provide additional drug targets and biomarkers to aid in the diagnosis and prognosis of many pathological conditions.
